These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 1545382

  • 1. A new approach to the study of ifosfamide metabolism by the analysis of human body fluids with 31P nuclear magnetic resonance spectroscopy.
    Martino R, Crasnier F, Chouini-Lalanne N, Gilard V, Niemeyer U, De Forni M, Malet-Martino MC.
    J Pharmacol Exp Ther; 1992 Mar; 260(3):1133-44. PubMed ID: 1545382
    [Abstract] [Full Text] [Related]

  • 2. Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy.
    Gilard V, Malet-Martino MC, de Forni M, Niemeyer U, Ader JC, Martino R.
    Cancer Chemother Pharmacol; 1993 Mar; 31(5):387-94. PubMed ID: 8431973
    [Abstract] [Full Text] [Related]

  • 3. Direct detection of new flucytosine metabolites in human biofluids by 19F nuclear magnetic resonance.
    Vialaneix JP, Malet-Martino MC, Hoffmann JS, Pris J, Martino R.
    Drug Metab Dispos; 1987 Mar; 15(5):718-24. PubMed ID: 2891491
    [Abstract] [Full Text] [Related]

  • 4. Direct detection of the intracellular formation of carboxyphosphamides using nuclear magnetic resonance spectroscopy.
    Boal JH, Ludeman SM, Ho CK, Engel J, Niemeyer U.
    Arzneimittelforschung; 1994 Jan; 44(1):84-93. PubMed ID: 8135883
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.
    Kerbusch T, Mathôt RA, Keizer HJ, Kaijser GP, Schellens JH, Beijnen JH.
    Drug Metab Dispos; 2001 Jul; 29(7):967-75. PubMed ID: 11408362
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
    Foxall PJ, Singer JM, Hartley JM, Neild GH, Lapsley M, Nicholson JK, Souhami RL.
    Clin Cancer Res; 1997 Sep; 3(9):1507-18. PubMed ID: 9815837
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.
    Kaijser GP, Keizer HJ, Beijnen JH, Bult A, Underberg WJ.
    Anticancer Res; 1996 Sep; 16(5B):3247-57. PubMed ID: 8920799
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Quantification of metabolites from two-dimensional nuclear magnetic resonance spectroscopy: application to human urine samples.
    Rai RK, Tripathi P, Sinha N.
    Anal Chem; 2009 Dec 15; 81(24):10232-8. PubMed ID: 19919088
    [Abstract] [Full Text] [Related]

  • 16. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1996 Aug 15; 383():1-370. PubMed ID: 12692653
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The analysis of ifosfamide and its metabolites (review).
    Kaijser GP, Korst A, Beijnen JH, Bult A, Underberg WJ.
    Anticancer Res; 1993 Aug 15; 13(5A):1311-24. PubMed ID: 8239501
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.